secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2026-06-04T12:00:41+00:00
Accession:  0001493152-26-027202
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA secures worldwide exclusive rights to MIRA-55 and SKNY-1 via amended license
--------------------------------------------------------------------------------

- Amended license with MIRALOGX LLC grants MIRA global exclusive rights to develop, commercialize, sublicense, and enforce IP for MIRA-55 and SKNY-1.
- Core economic terms from prior license arrangements remain materially unchanged; no upfront or milestone payments disclosed.
- MIRA CEO says the company now controls worldwide rights across entire pipeline: Ketamir-2, MIRA-55, and SKNY-1.
- MIRA-55 targets chronic inflammatory pain; SKNY-1 targets obesity and addiction-related disorders—both investigational.
- Agreement consolidates IP portfolio and enhances flexibility for future licensing and partnership opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226027202/0001493152-26-027202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226027202/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-027202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer